Post
Harnessing the power of cell and gene therapy in oncology
By 2029, the global cell and gene therapy market is projected to be worth more than $81bn, according to GlobalData’s …
New WHO hepatitis B guidelines address testing and treatment barriers
The World Health Organization (WHO) announced an update to guidance on the prevention, diagnosis, and treatment of chronic hepatitis B …
Changing epidemiology of atopic dermatitis in South Korea
The epidemiology of atopic dermatitis (AD) is heterogeneous across countries and age groups. Traditionally, AD in South Korea has always …
AAN 2024: Myostatin inhibitors on the horizon for the treatment of SMA
At the American Academy of Neurology (AAN) 2024 Annual Meeting, Biohaven presented its Phase III RESILIENT trial (NCT05337553), which investigates …
Vivasure implants first venous patient in PerQseal device trial
Vivasure Medical has treated the first venous patient in a clinical trial investigating its PerQseal Elite vascular closure system for …
Vivasure implants first venous patient in PerQseal device trial
Vivasure Medical has treated the first venous patient in a clinical trial investigating its PerQseal Elite vascular closure system for …
Two major breakthroughs in Fragile X Syndrome treatments
Spinogenix has received approval from the US Food and Drug Administration (FDA) for a Phase II clinical trial of SPG601 …
Edgewise reports data from trial of muscular dystrophy drug
US-based biotechnology company Edgewise Therapeutics has reported positive two-year topline data from the ARCH clinical trial of sevasemten (EDG-5506) in …
Actinogen treats first subject in Alzheimer’s disease therapy trial
Australian biotechnology company Actinogen Medical has treated the first subject in the XanaMIA Phase IIb clinical trial of Xanamem in …
FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits
The US Food and Drug Administration (FDA) has placed a clinical hold on the Phase I trial of Neumora Therapeutics’ …
Pulmocide’s inhaled antifungal shows promise in lung transplant patients
Pulmocide has announced evidence of prevention of pulmonary aspergillosis with pipeline candidate opelconazole after releasing topline data from a Phase …
AAN 2024: AbbVie and NeuroDerm highlight benefits of levodopa infusions in hope of US launch
At the American Academy of Neurology (AAN) 2024 Annual Meeting, further data on AbbVie’s Produodopa/Vyalev and NeuroDerm’s ND0612 (levodopa/carbidopa) were …
Study explores the effects of state Medicaid policies on hepatitis C treatment
The treatment of the hepatitis C virus (HCV) has been a controversial subject of health policy in the US, spurring …
Arrowhead Pharmaceuticals presents new Phase II data at the American College of Cardiology 2024
At the American College of Cardiology Scientific Sessions & Expo 2024 in Atlanta, Arrowhead Pharmaceuticals recently unveiled final data from …
AviadoBio treats first subject in trial of FTD-GRN therapy
UK-based biotechnology company AviadoBio has administered its investigational gene therapy, AVB-101, to the first subject in the Phase I/II ASPIRE-FTD …